Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ambrx Biopharma Inc.AMAM · Entity 109604 | Chief Financial Officer | July 05, 2023 | July 07, 2023 |
| ImmunityBio, Inc.NK · Entity 3618 | Chief Financial Officer | January 12, 2021 | January 13, 2021 |
| Motus GI Holdings, Inc.MOTS · Entity 93100 | Director | March 05, 2024 | March 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ambrx Biopharma Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2033-07-05 | Direct | 389,000 |
Reported balance
After 2023-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 389,000 · Balance 389,000 F1: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.
ImmunityBio, Inc.
Report date January 12, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,410 |
Ending reported balance
After 2021-01-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-01-12 · Exercise / conversion · Acquired 11,364 · Balance 31,774 Row 2 · 2021-01-12 · Sale · Disposed 16,364 · Balance 15,410 F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2028-08-27 | Direct | 165,907 |
Reported balance
After 2021-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-12 · Exercise / conversion · Disposed 11,364 · Balance 165,907 F2: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020.
F2: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022.
Motus GI Holdings, Inc.
Report date March 05, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2034-03-05 | Direct | 23,205 |
Reported balance
After 2024-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-05 · Grant · Acquired 23,205 · Balance 23,205 F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "Plan"). The option vests in its entirety on the first anniversary of the date of grant, March 5, 2025. The exercise price is based on the closing price for the shares of the common stock on the date of grant in accordance with the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "Plan"). The option vests in its entirety on the first anniversary of the date of grant, March 5, 2025. The exercise price is based on the closing price for the shares of the common stock on the date of grant in accordance with the terms of the Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ambrx Biopharma, Inc.
Report date March 07, 2024 · Filed March 07, 2024
Section 16 reporting ended · disclosed 2024-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 1
1 source rowRow 1 · 2024-03-07 · Disposition to issuer · Disposed 22,936 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive an amount equal to $28.00 per share in cash (the "Merger Consideration"), without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Disposition to issuer · Disposed 107,143 · Balance 0 F3: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of the Company Common Stock. F5: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F4: These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the "Grant Date"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-07 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of the Company Common Stock. F5: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F6: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2031-09-01 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-07 · Disposition to issuer · Disposed 367,799 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on June 30, 2022, and (ii) the remainder vests in thirty-six equal monthly installments following such date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2032-02-23 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-07 · Disposition to issuer · Disposed 121,427 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F9: The Company Common Stock subject to the Company Options vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on February 23, 2023, and (ii) the remainder vests in thirty-six equal monthly installments following such date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2032-02-23 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-07 · Disposition to issuer · Disposed 60,714 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F10: These Company Options are fully vested and exercisable. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.66 · Expires 2033-07-05 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-07 · Disposition to issuer · Disposed 55,571 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F11: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive an amount equal to $28.00 per share in cash (the "Merger Consideration"), without interest and less any applicable withholding taxes.
F3: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of the Company Common Stock.
F4: These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the "Grant Date"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date.
F5: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
F6: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter.
F7: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on June 30, 2022, and (ii) the remainder vests in thirty-six equal monthly installments following such date.
F8: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
F9: The Company Common Stock subject to the Company Options vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on February 23, 2023, and (ii) the remainder vests in thirty-six equal monthly installments following such date.
F10: These Company Options are fully vested and exercisable.
F11: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 55,571 | Not disclosed Strike: $16.66 | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 7 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,571 shares Expires 2033-07-05 F8 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F11 · derivative.exercise_date: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 60,714 | Not disclosed Strike: $1.96 | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 6 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,714 shares Expires 2032-02-23 F8 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F10 · derivative.exercise_date: These Company Options are fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 121,427 | Not disclosed Strike: $1.96 | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 5 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,427 shares Expires 2032-02-23 F8 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F9 · derivative.exercise_date: The Company Common Stock subject to the Company Options vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on February 23, 2023, and (ii) the remainder vests in thirty-six equal monthly installments following such date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 367,799 | Not disclosed Strike: $1.96 | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 4 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 367,799 shares Expires 2031-09-01 F8 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7 · derivative.exercise_date: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vested on June 30, 2022, and (ii) the remainder vests in thirty-six equal monthly installments following such date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of the Company Common Stock. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F6 · derivative.exercise_date: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. F6 · derivative.expiration_date: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 107,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · derivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,143 shares Expires not disclosed F3 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of the Company Common Stock. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F4 · derivative.exercise_date: These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the "Grant Date"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date. F4 · derivative.expiration_date: These RSUs vest as follows: (i) one-third (1/3) of the RSUs will vest on the 12-month anniversary of April 26, 2023 (the "Grant Date"), (ii) one-third (1/3) of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iii) one-third (1/3) of the RSUs will vest on the 36-month anniversary of the Grant Date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:41 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerCommon Stock | 22,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028182 · ownership.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive an amount equal to $28.00 per share in cash (the "Merger Consideration"), without interest and less any applicable withholding taxes. Read SEC document |
| March 05, 2024 Filed Mar 13, 2024 08:03 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 23,205 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001493152-24-009772 · ownership.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,205 Underlying: Common Stock, par value $0.0001 per share · 23,205 shares Expires 2034-03-05 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "Plan"). The option vests in its entirety on the first anniversary of the date of grant, March 5, 2025. The exercise price is based on the closing price for the shares of the common stock on the date of grant in accordance with the terms of the Plan. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 17:17 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069447 · ownership.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,776 F1 · security: Represents Restricted Stock Units ("RSUs") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the "Grant Date"). The RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan. F2 · shares: The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 17:00 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | SaleCommon Stock | 12,778 | $9.82 | $125,479.96 |
DisclosureSEC source: 0000950170-23-056944 · ownership.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,079 F1 · security: Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. ("Ambrx") becoming a Delaware corporation (the "Domestication"). Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units ("RSUs") payable in Ambrx common stock granted to the Reporting Person as previously disclosed. F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs. The sale is mandated by Ambrx's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale is being made pursuant to the Reporting Person's effective 10b5-1 plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.99. The Reporting Person undertakes to provide to Ambrx, any security holder of Ambrx or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. ("Ambrx") becoming a Delaware corporation (the "Domestication"). Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units ("RSUs") payable in Ambrx common stock granted to the Reporting Person as previously disclosed. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:05 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 389,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-23-032230 · ownership.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,000 Underlying: Ordinary Shares · 389,000 shares Expires 2033-07-05 F1 · derivative.exercise_price: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 18:00 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantOrdinary Shares | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026101 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. F2 · shares: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: (i) 25% of the RSUs will vest on the six-month anniversary of the grant date of April 26, 2023 (the "Grant Date"), (ii) 25% of the RSUs will vest on the 12-month anniversary of the Grant Date, (iii) 25% of the RSUs will vest on the 24-month anniversary of the Grant Date, and (iv) 25% of the RSUs will vest on the 36-month anniversary of the Grant Date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantEmployee Stock Option (right to buy) · Derivative | 425,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 6 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Ordinary Shares · 425,000 shares Expires 2032-02-22 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 425,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 5 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 425,000 shares Expires 2032-02-22 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantEmployee Stock Option (right to buy) · Derivative | 850,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 4 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Ordinary Shares · 850,000 shares Expires 2032-02-22 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F4 · derivative.exercise_date: Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 850,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 850,000 shares Expires 2032-02-22 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F4 · derivative.exercise_date: Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantEmployee Stock Option (right to buy) · Derivative | 2,574,596 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,574,596 Underlying: Ordinary Shares · 2,574,596 shares Expires 2031-09-01 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F1 · derivative.exercise_date: Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:16 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 2,574,596 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001209191-23-005791 · doc4.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Fin. & Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,574,596 shares Expires 2031-09-01 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F1 · derivative.exercise_date: Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 17:06 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001493152-22-004051 · ownership.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.0001 per share · 50,000 shares Expires 2032-02-10 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:45 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-000691 · ownership.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,709 F1 · shares: On January 5, 2022, Reporting Person was granted 82,500 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for calendar year 2022, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:13 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-21-033779 · ownership.xml · derivative · entry 2 Nelson Sonja · CIK 0001674905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-22 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2016 Plan. The option becomes exercisable as to 50% of the shares on June 22, 2022, and the remaining shares will become exercisable on June 22, 2023. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:13 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 18,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-033779 · ownership.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,209 F1 · shares: On June 22, 2021, Reporting Person was granted 18,209 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for the remainder of calendar year 2021, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan") Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:19 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 11,364 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-21-003421 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,907 Underlying: Common Stock · 11,364 shares Expires 2028-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:19 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 16,364 | $15.00 | $245,460.00 |
DisclosureSEC source: 0001209191-21-003421 · doc4.xml · nonDerivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,410 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:19 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 11,364 | $3.07 | $34,887.48 |
DisclosureSEC source: 0001209191-21-003421 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 22,729 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-21-002393 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,271 Underlying: Common Stock · 22,729 shares Expires 2028-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 39,271 | $13.62 | $534,937.78 |
DisclosureSEC source: 0001209191-21-002393 · doc4.xml · nonDerivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,410 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020. F2 · price: Represents the weighted average share price of an aggregate total of 39,271 shares sold in the price range of $13.31 to $14.015 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 22,729 | $3.07 | $69,778.03 |
DisclosureSEC source: 0001209191-21-002393 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2020 Filed Aug 4, 2020 21:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044914 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. Read SEC document |
| August 02, 2020 Filed Aug 4, 2020 21:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Tax withholdingCommon Stock | 3,458 | $11.18 | $38,660.44 |
DisclosureSEC source: 0001209191-20-044914 · doc4.xml · nonDerivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,952 Read SEC document |
| August 02, 2020 Filed Aug 4, 2020 21:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044914 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · price: On August 2, 2020, 10,000 of the reporting person's restricted stock units vested. The closing price of the issuer's common stock on July 31, 2020 was the price used to calculate the shares withheld. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 17:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020979 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs vested on March 23, 2020. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs vested on March 23, 2020. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 17:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Tax withholdingCommon Stock | 6,132 | $2.82 | $17,292.24 |
DisclosureSEC source: 0001209191-20-020979 · doc4.xml · nonDerivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,410 Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 17:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020979 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:46 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044647 · doc4.xml · derivative · entry 3 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:46 UTC | ImmunityBio, Inc. NK · Entity 3618 | Tax withholdingCommon Stock | 3,458 | $1.27 | $4,391.66 |
DisclosureSEC source: 0001209191-19-044647 · doc4.xml · nonDerivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,542 Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:46 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044647 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:58 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-18-048877 · doc4.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-08-27 F1 · derivative.exercise_date: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 17:40 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045353 · doc4.xml · derivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 25% of the RSUs will vest on August 2, 2019, and 25% of the RSUs will vest annually thereafter, such that the award will be fully vested on August 2, 2022. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 18:55 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021664 · doc4.xml · derivative · entry 2 Nelson Sonja · CIK 0001674905 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock. F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020. F1 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 18:55 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021664 · doc4.xml · nonDerivative · entry 1 Nelson Sonja · CIK 0001674905 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.